In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Dova Pharmaceuticals Inc (DOVA), with a price target of $18. The company’s shares opened today at $8.54, close to its 52-week low of $5.62.
Pantginis observed:
“Valuation and risks to price target achievement. We maintain our Buy rating and $18 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunity for avatrombopag in the CLD, cITP, and CIT indications broken down as follows: (1) CLD contributes 61.1% of our valuation ($206 million peak sales projection in the U.S.); (2) cITP contributes 31.8% of our valuation ($174 million peak sales projection in the U.S.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.9% and a 34.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dova Pharmaceuticals Inc with a $18 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35.33 and a one-year low of $5.62. Currently, Dova Pharmaceuticals Inc has an average volume of 153.7K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DOVA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.
